Search company, investor...
Nexcelom Bioscience company logo

Nexcelom Bioscience

Founded Year



Acquired | Acquired



About Nexcelom Bioscience

Nexcelom Bioscience designs, develops, and manufactures devices and instruments for cell-based assays used in cancer research, vaccine development, stem cell research, infectious disease treatment and drug discovery. On May 12, 2021, Nexcelom Bioscience was acquired by PerkinElmer. The terms of the transaction were not disclosed.

Headquarters Location

360 Merrimack Street Building 9

Lawrence, Massachusetts, 01843,

United States


Missing: Nexcelom Bioscience's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Nexcelom Bioscience's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Nexcelom Bioscience

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Nexcelom Bioscience is included in 2 Expert Collections, including Regenerative Medicine.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Nexcelom Bioscience Patents

Nexcelom Bioscience has filed 14 patents.

The 3 most popular patent topics include:

  • Biotechnology
  • Cell biology
  • Cell culture
patents chart

Application Date

Grant Date


Related Topics




Yeasts, Cell biology, Molecular biology, Biotechnology, Microscopy


Application Date


Grant Date



Related Topics

Yeasts, Cell biology, Molecular biology, Biotechnology, Microscopy



Latest Nexcelom Bioscience News

Global Cell Counting Market Worth around US$ 8.16 Billion in 2022, and Increase at a Growth Rate of 9% from 2022 to 2032

Nov 16, 2022

News Provided By Share This Article Cell Counting Market Market Study on Global Cell Counting Market: Rising Burden of Chronic Illness to Drive the Demand for Cell Counting Techniques NEW YORK, UNITED STATES, November 16, 2022 / / -- The net worth of the global cell counting market was estimated to be around US$ 8.16 Billion in 2022, and it is anticipated to increase at a growth rate of 9% from 2022 to 2032. One of the reasons influencing the market's expansion is the great potential of biologics to cure chronic illnesses. The use of different cell counting tools during the creation of biologics is expected to take the overall valuation of the global cell counting market share up to US$ 19 Billion. Blood cell counting is essential for the evaluation of numerous illnesses, and its usage is likely to rise throughout the forecast period. Numerous research fields, including neurology, cancer biology, and immunology, which have lucrative market growth prospects, are gradually adopting cell counting instruments nowadays. Therefore, the global cell counting market is also expected to see exponential growth. Research studies employ cytometers to measure criteria, including physical characteristics, kind, and lineage, in order to track the evolution of viruses, diseases, and other microorganisms. The category is further driven by strategic actions taken by major market participants to cater to the growing number of research institutes in emerging economies. A study titled "Potential of an Automated- and Image-Based Cell Counter to Accelerate Microalgal Research and Applications" found that an image-based and automated cell counter contributes to the development of routine microalgal management with a lower work strain when in contrast to conventional approaches such as hemocytometry and turbidity. The widespread use of cytometers in cell biology research investigations can be cited for the largest share of this segment. At the UAE University in Al Ain, for instance, Alliance Global deployed an automated cell counter system in March 2021. While the other sub-segment for reagents had the highest revenue share in terms of volume in the historical years. The significant revenue share is related to the frequent acquisition of these items for use in automated cell counters, hemocytometry, and spectrophotometry. Request for Free Sample Report Copy of : Key Takeaways of the Global Cell Counting Market Study • The demand for cell counting instruments is heightened by the requirement for periodic calibrations before beginning experiments. • According to the global cell counting market analysis report, consumables and accessories would contribute to more than 50% of total revenue generated during the forecast years. • The greatest income share in 2021 —more than 35%— was accounted for by research and academic institutions. Know the methodology of report: Competitive Landscape for the Global Cell Counting Market Players Some of the prominent players in the global cell counting market are ThermoFisher Scientific, Inc., Merck KGaA, Agilent Technologies, PerkinElmer, Inc., BD, Danaher, Bio-Rad Laboratories, Inc., BioTek Instruments, Inc., GE Healthcare, and DeNovix Inc. among others Recent Developments in the Global Cell Counting Market • In March 2022, Mindray Company strengthened its product portfolio by including both complete blood count (CBC) and erythrocyte sedimentation rate (ESR) tests in its new BC-700 product series, which was introduced. • Abacus dx and Luminex Companies announced a new agreement in February 2022 for the Guava line of flow cytometry tools and supplies. According to the agreement, Abacus dx will distribute the Guava line of flow cytometry tools and supplies from Luminex. • PerkinElmer revealed in May 2021 that it had acquired Nexcelom Bioscience in order to increase its cell biology expertise. With the purchase, PerkinElmer gains access mostly to the cell counting product line from Nexcelom Bioscience which could help expand its QA/QC capabilities. Get full access of report: Want to Know More? Persistence Market Research, a research and consulting firm, has published a revised market research report on the electric cargo bike market that contains a global industry analysis of 2017–2021 and an opportunity assessment for 2022–2032. The report provides in-depth analysis of the market through different segments, namely, product type, battery type, end use, and region. Also, Check Other Trending Reports: • Orthopedic Veterinary Implants Market - • Orthopedic Surgical Robots Market - About Persistence Market Research: Business intelligence is the foundation of every business model employed by Persistence Market Research. Multi-dimensional sources are being put to work, which include big data, customer experience analytics, and real-time data collection. Thus, working on “micros” by Persistence Market Research helps companies overcome their “macro” business challenges. Persistence Market Research is always way ahead of its time. In other words, it tables market solutions by stepping into the companies’/clients’ shoes much before they themselves have a sneak pick into the market. The pro-active approach followed by experts at Persistence Market Research helps companies/clients lay their hands on techno-commercial insights beforehand, so that the subsequent course of action could be simplified on their part. Persistence Market Research Pvt Ltd Atul Singh PMR

Nexcelom Bioscience Frequently Asked Questions (FAQ)

  • When was Nexcelom Bioscience founded?

    Nexcelom Bioscience was founded in 2003.

  • Where is Nexcelom Bioscience's headquarters?

    Nexcelom Bioscience's headquarters is located at 360 Merrimack Street, Lawrence.

  • What is Nexcelom Bioscience's latest funding round?

    Nexcelom Bioscience's latest funding round is Acquired.

  • Who are the investors of Nexcelom Bioscience?

    Investors of Nexcelom Bioscience include PerkinElmer, Ampersand Capital Partners, Massachusetts Growth Capital Corporation and Merrimack Valley Economic Development Council.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.